

Jason R Stubbs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9374387/publications.pdf>

Version: 2024-02-01

30
papers

1,379
citations

567144

15
h-index

526166

27
g-index

45
all docs

45
docs citations

45
times ranked

2035
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 305-313.	3.0	323
2	Role of Hyperphosphatemia and 1,25-Dihydroxyvitamin D in Vascular Calcification and Mortality in Fibroblastic Growth Factor 23 Null Mice. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 2116-2124.	3.0	241
3	FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2014, 307, E426-E436.	1.8	138
4	PHOSPHORUS METABOLISM AND MANAGEMENT IN CHRONIC KIDNEY DISEASE: Role of Fibroblast Growth Factor 23 in Phosphate Homeostasis and Pathogenesis of Disordered Mineral Metabolism in Chronic Kidney Disease. <i>Seminars in Dialysis</i> , 2007, 20, 302-308.	0.7	122
5	Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 38-46.	3.1	92
6	Development and validation of a simple UHPLC-MS/MS method for the simultaneous determination of trimethylamine N-oxide, choline, and betaine in human plasma and urine. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 109, 128-135.	1.4	54
7	Trimethylamine N-Oxide and Cardiovascular Outcomes in Patients with ESKD Receiving Maintenance Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 261-267.	2.2	48
8	Microbiome and Cardiovascular Disease in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1598-1604.	2.2	47
9	Deoxycholic Acid, a Metabolite of Circulating Bile Acids, and Coronary Artery Vascular Calcification in CKD. <i>American Journal of Kidney Diseases</i> , 2018, 71, 27-34.	2.1	46
10	Decreased Conversion of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 Following Cholecalciferol Therapy in Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1965-1973.	2.2	40
11	Dietary phosphate restriction suppresses phosphaturia but does not prevent FGF23 elevation in a mouse model of chronic kidney disease. <i>Kidney International</i> , 2013, 84, 713-721.	2.6	29
12	Development and validation of a UHPLC-MS/MS method for measurement of a gut-derived uremic toxin panel in human serum: An application in patients with kidney disease. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 174, 618-624.	1.4	24
13	Decreased Kidney Function Is Associated with Enhanced Hepatic Flavin Monooxygenase Activity and Increased Circulating Trimethylamine N-Oxide Concentrations in Mice. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1304-1309.	1.7	23
14	Cholecalciferol vs. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial. <i>British Journal of Nutrition</i> , 2016, 116, 2074-2081.	1.2	22
15	Trimethylamine-N-oxide acutely increases cardiac muscle contractility. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2020, 318, H1272-H1282.	1.5	17
16	Does it Matter How Parathyroid Hormone Levels are Suppressed in Secondary Hyperparathyroidism?. <i>Seminars in Dialysis</i> , 2011, 24, 298-306.	0.7	16
17	Dietary phosphate restriction attenuates polycystic kidney disease in mice. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, F35-F42.	1.3	16
18	DCLK1 isoforms and aberrant Notch signaling in the regulation of human and murine colitis. <i>Cell Death Discovery</i> , 2021, 7, 169.	2.0	14

#	ARTICLE	IF	CITATIONS
19	Is fibroblast growth factor 23 a harbinger of mortality in CKD?. <i>Pediatric Nephrology</i> , 2012, 27, 697-703.	0.9	11
20	Metabolic Activation of Flavin Monooxygenase-mediated Trimethylamine-N-Oxide Formation in Experimental Kidney Disease. <i>Scientific Reports</i> , 2019, 9, 15901.	1.6	10
21	Randomized, Placebo-Controlled Trial of Rifaximin Therapy for Lowering Gut-Derived Cardiovascular Toxins and Inflammation in CKD. <i>Kidney360</i> , 2020, 1, 1206-1216.	0.9	10
22	Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease. <i>Kidney International Reports</i> , 2021, 6, 953-961.	0.4	9
23	Fibroblast growth factor 23: uremic toxin or innocent bystander in chronic kidney disease?. <i>Nephrology News & Issues</i> , 2009, 23, 33-4, 36-7.	0.1	9
24	Dietary Interventions Ameliorate Infectious Colitis by Restoring the Microbiome and Promoting Stem Cell Proliferation in Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 339.	1.8	9
25	Kidney stone formation in a novel murine model of polycystic kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2022, 323, F59-F68.	1.3	3
26	Critical Role of Osteopontin in Maintaining Urinary Phosphate Solubility in CKD. <i>Kidney360</i> , 0, 3, 10.34067/KID.0007352021.	0.9	3
27	Contribution of phosphate and FGF23 to CKD progression. <i>Current Opinion in Nephrology and Hypertension</i> , 2022, Publish Ahead of Print, .	1.0	2
28	Response to "Fibroblast Growth Factor 23 Is a Valuable Predictor of Autosomal Dominant Polycystic Kidney Disease Progression". <i>Kidney International Reports</i> , 2021, 6, 1482-1483.	0.4	0
29	Direct hypertrophic effects of fibroblast growth factor 23 on cardiomyocytes. <i>FASEB Journal</i> , 2012, 26, 1143.4.	0.2	0
30	The Acute Inotropic Effect of the Uremic Metabolite, Trimethylamine-N-Oxide (TMAO), on Human Cardiac Muscle. <i>FASEB Journal</i> , 2018, 32, 901.11.	0.2	0